StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
NASDAQ:TTNP opened at $3.30 on Friday. The company’s 50-day simple moving average is $3.71 and its 200-day simple moving average is $4.91. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- What is the NASDAQ Stock Exchange?
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- What is the Hang Seng index?
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- What is a Stock Market Index and How Do You Use Them?
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
